Most ebook files are in PDF format, so you can easily read them using various software such as Foxit Reader or directly on the Google Chrome browser.
Some ebook files are released by publishers in other formats such as .awz, .mobi, .epub, .fb2, etc. You may need to install specific software to read these formats on mobile/PC, such as Calibre.
Please read the tutorial at this link. https://ebooknice.com/page/post?id=faq
We offer FREE conversion to the popular formats you request; however, this may take some time. Therefore, right after payment, please email us, and we will try to provide the service as quickly as possible.
For some exceptional file formats or broken links (if any), please refrain from opening any disputes. Instead, email us first, and we will try to assist within a maximum of 6 hours.
EbookNice Team
Status:
Available4.7
9 reviews
ISBN 10: 0415296986
ISBN 13: 9780415296984
Author: Hans Stauss, Yutaka Kawakami, Giorgio Parmiani
Recent progress in fundamental tumor immunology has led to immunotherapy trials in patients with solid tumors and hematological malignancies. In the past, immunotherapy approaches were primarily based on enhancement of tumor immunity with cytokines and adjuvant therapy, without knowledge of relevant tumor antigens. The discovery of tumor antigens
Part 1: Animal models
Chapter 1: Mouse models in the recognition of tumor antigens
Summary
Introduction
Animal tumor models
References
Chapter 2: Role of heat shock protein in chaperoning tumor antigens and modulating anti-tumor immunity
Summary
Introduction: discovery of HSPs in chaperoning anti-tumor immunity
Roles of major mammalian HSPs in immune responses
Conclusion: immunological principles associated with HSPs
Perspectives
References
Part 2: Human tumor antigens recognized by class I HLA-restricted T cells
Chapter 3: WT1 as target for tumor immunotherapy
Summary
WT1 structure
WT1 function during embryogenesis
WT1 function in post-natal life
WT1 function in tumors
WT1-based immunotherapy
Avoiding immunological tolerance
Anti-WT1 CTL in leukemia
Can self-restricted CTL protect against WT1 expressing tumors?
Immunotherapy via TCR transfer
References
Chapter 4: Human melanoma antigens recognized by CD8+ T cells
Summary
Introduction
Methods for the identification of antigens recognized by CD8+ T cells
Characteristics of the identified melanoma antigens recognized by CD8 + T cells and their implications to development of immunotherapy
Implication of the identification of MHC class I restricted melanoma antigens for the understanding of immune responses to melanoma cells and the development of immunotherapy
Concluding remarks
References
Chapter 5: Squamous cell and adeno cancer antigens recognized by cytotoxic T lymphocytes
Summary
Introduction
TAAs of SCC and adenocarcinoma
Tumor-associated antigens of pancreatic cancer
Multidrug resistance-associated protein 3 (MRP3) is a new TAA
Conclusion
References
Chapter 6: Altered peptide ligands of tumor T-cell epitopes: implications for more effective vaccine therapy in human neoplasia
Summary
Introduction
The TCR: a flexible and tunable structure for antigen recognition by T cells
Interaction between T cells and their targets: structure of the HLA/peptide complex
APL for finely tuning anti-tumor T-cell reactivity
Peptide optimized for HLA binding or bioavailability
Peptide optimized at TCR contact residues
Potential limitations to the use of tumor antigen-derived APL
In vivo efficacy of APL-based vaccine in neoplastic disease
Role of APL in tumor-induced T-cell anergy and immune escape
Conclusions
References
Chapter 7: Ex vivo and in situ detection of tumor-specific T-cell immunity with MHC tetramers
Summary
Detection of antigen-specific T-cell immunity with multimeric MHC technology
Production of MHC class I tetramers and detection of antigen-specific CD8+ T cells
Conditions of binding
Data acquisition and analysis
Detection of naturally occurring tumor-specific CD8 + T-cell immunity by tetramer flow cytometry
Phenotype and function of melanoma-reactive T cells
Therapy-induced T-cell responses
Additional technologies
Acknowledgments
References
Part 3: Human tumor antigens recognized by class II HLA-restricted T cells
Chapter 8: Antigens of the MAGE family recognized by CD4+ T cells
Summary
Introduction
The MAGE gene family
Experimental approaches for the identification of HLA class II-restricted tumor antigen epitopes
MAGE-A3 encoded epitopes recognized by CD4+ T cells
Acknowledgments
Chapter 9: Melanoma antigens recognized by CD4+ T cells
Summary
Introduction
The need for identification of MHC class II-restricted tumor antigens
The role of CD4+ T cells in immune response
Approach to identification of tumor antigens recognized by CD4+ T cells
MHC class II-restricted melanoma antigens
Development of cancer vaccines based on molecularly defined tumor antigens
References
Part 4: Human tumor antigens recognized by antibodies
Chapter 10: Human tumor antigens recognized by antibodies (SEREX)
Summary
Introduction
Material and methods
Results
Discussion
References
Chapter 11: Antibodies to human tumor oncoproteins in cancer patients
Summary
Introduction
The human antibody response to p53 in cancer patients
The human antibody response to HER-2/neu in cancer patients
Antibodies against cancer-related proteins important in malignant transformation or progression
Measurement of antibodies to oncogenic proteins evolves from a research to a clinical tool
Analysis of antibody responses to human oncoproteins in control populations
Conclusion
Acknowledgments
References
Chapter 12: Antibody and T-cell responses to the NY-ESO-1 antigen
Summary
Cancer-testis antigen NY-ESO-1
Antibody reactivity against NY-ESO-1
NY-ESO-1 specific CD4+ T-cell reactivity
NY-ESO-1 specific CD8+ T-cell reactivity
Primary induction of NY-ESO-1 specific CD8+ T-cell responses in vivo
tumor antigens list
tumor antigens definition
tumor associated antigens list
tumor-associated antigens
a tumor-specific antigen is quizlet
Tags: Hans Stauss, Yutaka Kawakami, Giorgio Parmiani, Tumor Antigens
4.6
12 reviews
4.3
20 reviews
4.7
9 reviews
4.3
36 reviews